Bayesian Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Bayesian Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-5,434	Closed	-$219K	–	795
2018 Q4	$219K	Buy	+5,434	New	+$280K	0.04%	497
2018 Q1	–	Sell	-5,231	Closed	-$279K	–	859
2017 Q4	$279K	Buy	+5,231	New	+$291K	0.06%	430
2016 Q4	–	Sell	-3,032	Closed	-$212K	–	731
2016 Q3	$212K	Buy	+3,032	New	+$168K	0.14%	273

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Bayesian Capital Management's EGRX Position: Q1 2019 in Review

Bayesian Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2019, closing a stake of 5,434 shares — an estimated $219K sold.

Bayesian Capital Management first reported a position in EGRX in Q3 2016 and held it in 3 quarters. The position peaked at $279K in Q4 2017. 182 funds tracked by Wall St. Rank hold EGRX as of Q1 2019.

Bayesian Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
Bayesian Capital Management sold 5,434 Eagle Pharmaceuticals, Inc. shares in Q1 2019, an estimated $219K.
Bayesian Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2016 and held it in 3 quarters.
Bayesian Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $279K in Q4 2017.
182 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2019.

Based on Bayesian Capital Management's 13F filing for Q1 2019, filed 14 May 2019.